Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 1-year average of 22.43%, around the middle of its 1-year range (-48.09%–80.27%).
100.00% below its 12-month average of 22.43%.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-06-30): -48.09%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
22.43%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$81.31M
Gross Margin
77.06%
TTM Avg
74.09%
3Y Avg
74.09%
5Y Avg
72.46%
Market Cap
$80.49M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$84.52M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
Market Cap
$84.87M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$85.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$85.90M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $81.82M | 0.00% | 22.43% | 0.00% | N/A |
| LENSAR Inc (LNSR)vs › | $81.67M | 47.96% | 47.37% | 50.31% | 51.06% |
| Pulmonx Corporation (LUNG)vs › | $81.31M | 77.06% | 74.09% | 74.09% | 72.46% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $80.49M | 100.00% | 100.00% | 100.00% | 100.00% |
| MediciNova, Inc. (MNOV)vs › | $84.17M | 7.58% | 3.79% | 26.89% | 34.60% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.52M | 82.44% | 83.07% | -40.55% | -241.44% |
| Humacyte, Inc. (HUMA)vs › | $84.87M | -736.46% | -368.23% | -290.99% | -1574.61% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Conexeu Sciences Inc. (CNXU)vs › | $86.43M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -48.09% |
| 2026-03-31 | 80.27% |
| 2025-12-31 | 79.99% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
